药物洗脱支架血栓形成的机制及防治进展  

Drug-eluting Stent Thrombosis:the Pathological Mechanism,Prevention and Treatment

作　　者：张学丽[1] 李健[1] 李丹[1] 安毅[1] 

机构地区：[1]青岛大学医学院附属医院心内科,山东青岛266000

出　　处：《医学综述》2014年第17期3083-3086,共4页Medical Recapitulate

基　　金：国家自然基金面上项目(81071246);山东省自然基金面上项目(ZR2010HM081)

摘　　要：支架内血栓(ST)形成是经皮冠状动脉介入术治疗后少见的,但却是严重的甚至危及生命的并发症。与金属裸支架相比,药物洗脱支架已使再狭窄的发生率降低,但却使术后ST形成的发生率升高。支架内皮化不全或不内皮化是导致血栓形成的主要原因之一,如何提高支架的内皮化是临床研究的热点。研制新型抗血小板药物、提高支架置入水平,研发新型支架、基因治疗、重视冠心病的二级预防等是预防ST形成的有效措施。Stent thrombosis（ST） is a complication after percutaneous coronary intervention. It is rare, but is serious and even life-threatening. Compared with bare-metal stent, drug-eluting stent has reduced the incidence of restenosis,but has a higher incidence of stent thrombosis. One of the main reasons leading to thrombosis is incomplete endothelialization or unendothelialization, and how to improve stent endothelialization is a hotspot in clinical. The effective measures to prevent ST include ： developing new antiplatelet agents, improving the level of stent placement, researching new scaffolds, gene therapy, emphasis on the secondary prevention of coronary heart disease.

关 键 词：经皮冠状动脉介入术 药物洗脱支架 支架内血栓 抗血小板药物治疗抵抗 

分 类 号：R541.4[医药卫生—心血管疾病]